Astellas Entered into a License Agreement with 4D Molecular Therapeutics for Rare Ophthalmic Targets Using 4DMT's Intravitreal R100 Vector
Shots:
- 4DMT will receive $20M up front, and future option fees and milestones of ~$942.5M incl. near-term development milestones of ~$15M for the initial target along with royalties on net sales of all licensed products
- Astellas obtains rights to use intravitreal retinotropic R100 vector (invented by 4DMT) to deliver its own genetic payloads for one genetic target in rare monogenic ophthalmic disease & also get the option for 3 additional targets after paying additional option exercise fees
- Astellas will be responsible for research, development, manufacturing, and commercialization activities. 4DMT will maintain rights to the use of R100 for large-market non-hereditary ophthalmic diseases
Ref: PR Newswire | Image: Astellas
Related News:- Astellas Signed a Research Collaboration and Exclusive Option Agreement with Cullgen to Advance Innovative Targeted Protein Degraders
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
